Hamburg pushes science, enforcement in FDA strategy

A regulatory environment driven by developments in science and technology is high on Margaret Hamburg's list of strategic priorities. She considers herself an advocate for the field of regulatory science and a champion of its evolution.

The FDA yesterday released the 50-page Strategic Priorities 2011 - 2015: Responding to the Public Health Challenges of the 21st Century. The document identifies five "cross-cutting areas," including regulatory science. The remaining four target safety in the global supply chain; stronger compliance and enforcement activities; greater attention to such special populations as women, minorities and children; and emergency medical countermeasures.

Regarding compliance and enforcement, the document recaps recent FDA changes, including deadlines for warning letter responses and the means to prioritize post-warning-letter/post-recall follow-up plant inspections. New programs will "sharpen the effectiveness and timeliness of regulatory, compliance and enforcement systems."

- see the FDA release
- here's the document

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.